Quote this publication Share Print

TRAVATAN (travoprost), glaucoma eye drops

OPHTHALMOLOGY - New indication
Opinions on drugs - Posted on Feb 03 2017

Reason for request

Extension of indication

No clinical benefit demonstrated in paediatric patients, by comparison with its comparators, in the reduction of elevated intraocular pressure


  • TRAVATAN now has Marketing Authorisation in the reduction of elevated intraocular pressure (IOP), from 2 months of age, in paediatric patients with intraocular hypertension or glaucoma.
  • A study has demonstrated its non-inferiority relative to timolol after 12 weeks of treatment on the reduction of IOP in children.
  • No long-term safety data are available.
  • TRAVATAN contains excipients that may cause a skin reaction.



Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments